Literature DB >> 12388721

Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus.

David Favre1, Véronique Blouin, Nathalie Provost, Radec Spisek, Françoise Porrot, Delphine Bohl, Frederic Marmé, Yan Chérel, Anna Salvetti, Bruno Hurtrel, Jean-Michel Heard, Yves Rivière, Philippe Moullier.   

Abstract

We previously documented persistent regulation of erythropoietin (Epo) secretion in mice after a single intramuscular (i.m.) injection of a recombinant adeno-associated virus (rAAV) vector harboring both the tetracycline-dependent transactivator (rtTA) and the Epo cDNA (D. Bohl, A. Salvetti, P. Moullier, and J. M. Heard, Blood 92:1512-1517, 1998). Using the same vector harboring the cynomolgus macaque Epo cDNA instead, the present study evaluated the ability of the tetracycline-regulatable (tetR) system to establish long-term transgene regulation in nonhuman primates. The vector was administered i.m., after which 5-day induction pulses were performed monthly for up to 13 months by using doxycycline (DOX), a tetracycline analog. We show that initial inductions were successful in all individuals and that there was a tight regulation and a rapid deinduction pattern upon DOX withdrawal. For one macaque, regulation of Epo secretion was maintained during the entire experimental period; for the five remaining macaques, secreted Epo became indistinguishable from endogenous Epo upon repeated DOX inductions. We investigated the mechanism involved and showed that, except in the animal in which secretion persisted, delayed humoral and cellular immune responses were directed against the rtTA transactivator protein associated with the reduction of vector DNA in transduced muscles. This study provides some evidence that, when the immune system is not mobilized against the rtTA transactivator, the tetR-regulatable system is able to support long-term transgene regulation in the context of an rAAV in nonhuman primates. In addition, our results suggest potential improvements for vector design.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388721      PMCID: PMC136781          DOI: 10.1128/jvi.76.22.11605-11611.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice.

Authors:  D No; T P Yao; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

4.  A humanized system for pharmacologic control of gene expression.

Authors:  V M Rivera; T Clackson; S Natesan; R Pollock; J F Amara; T Keenan; S R Magari; T Phillips; N L Courage; F Cerasoli; D A Holt; M Gilman
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

5.  Recombinant adeno-associated virus for muscle directed gene therapy.

Authors:  K J Fisher; K Jooss; J Alston; Y Yang; S E Haecker; K High; R Pathak; S E Raper; J M Wilson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

6.  Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity.

Authors:  S Urlinger; U Baron; M Thellmann; M T Hasan; H Bujard; W Hillen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

7.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.

Authors:  K J Fisher; G P Gao; M D Weitzman; R DeMatteo; J F Burda; J M Wilson
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 8.  Mechanisms underlying expression of Tn10 encoded tetracycline resistance.

Authors:  W Hillen; C Berens
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

9.  Transcriptional activation by tetracyclines in mammalian cells.

Authors:  M Gossen; S Freundlieb; G Bender; G Müller; W Hillen; H Bujard
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

10.  Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors.

Authors:  S K Tripathy; H B Black; E Goldwasser; J M Leiden
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  44 in total

Review 1.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 2.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

3.  Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity.

Authors:  Mickaël Guilbaud; Marie Devaux; Celia Couzinié; Johanne Le Duff; Alice Toromanoff; Céline Vandamme; Nicolas Jaulin; Gwladys Gernoux; Thibaut Larcher; Philippe Moullier; Caroline Le Guiner; Oumeya Adjali
Journal:  Hum Gene Ther       Date:  2019-04-16       Impact factor: 5.695

Review 4.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Authors:  Pedro R Lowenstein; Ronald J Mandel; Wei-Dong Xiong; Kurt Kroeger; Maria G Castro
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

Review 5.  Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?

Authors:  Jeffrey H Kordower; C Warren Olanow
Journal:  Exp Neurol       Date:  2007-08-22       Impact factor: 5.330

6.  Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors.

Authors:  Elsa Lhériteau; Lyse Libeau; Alexandra Mendes-Madeira; Jack-Yves Deschamps; Michel Weber; Guylène Le Meur; Nathalie Provost; Caroline Guihal; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2010-03-30       Impact factor: 11.454

7.  Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle.

Authors:  Alice Toromanoff; Oumeya Adjali; Thibaut Larcher; Marcelo Hill; Lydie Guigand; Pierre Chenuaud; Jack-Yves Deschamps; Olivier Gauthier; Gilles Blancho; Bernard Vanhove; Fabienne Rolling; Yan Chérel; Philippe Moullier; Ignacio Anegon; Caroline Le Guiner
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

8.  A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.

Authors:  Clayton P Santiago; Casey J Keuthan; Sanford L Boye; Shannon E Boye; Aisha A Imam; John D Ash
Journal:  Mol Ther       Date:  2018-07-19       Impact factor: 11.454

9.  Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors.

Authors:  Y Han; Q A Chang; T Virag; N C West; D George; M G Castro; M C Bohn
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

10.  Characterization of a molecular switch system that regulates gene expression in mammalian cells through a small molecule.

Authors:  Jennifer L Taylor; Priyanka Rohatgi; H Trent Spencer; Donald F Doyle; Bahareh Azizi
Journal:  BMC Biotechnol       Date:  2010-02-18       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.